INTRODUCTION
The transmembrane glycoprotein CD4 is a major molecular partner in the immunological synapse which leads to optimal activation of T lymphocytes during immune responses (1) . CD4 also serves as the primary receptor for the human immunodeficiency virus (HIV) 1 , thereby allowing the virus to enter cells (2) . At present, redesigned recombinant anti-CD4 antibodies (3−6) or a fully human anti-CD4 antibody from human immunoglobulin transgenic mice (7) are currently included in phase I−III trials for the treatment of autoimmune diseases, allograft rejection, or AIDS. We have expressed the humanized anti-CD4 recombinant Fab 13B8.2 in the baculovirus/insect cell system which is directed against the CDR3-like region of the D1 domain of CD4 (8) . In vitro, this antibody prevents HIV transcription in CD4 + cells at a post gp120 binding step (8, 9) and also inhibits antigen presentation (8) . Early phase I clinical trials (10, 11, 12) using murine 13B8.2 antibody led to clinical benefits for some HIV-infected patients, i.e., disappearance of circulating p24 antigen (10, 12) together with negativation of the reverse transcriptase assay (10) or generation of serum antibodies to gp120 and HIV-neutralizing antibodies (12) .
The identification of critical residues from the antibody paratope involved in CD4
binding is a prerequisite to the improvement of such recombinant antibody for future clinical trials. To this end, we previously characterized CD4-immunoreactive peptides in the 13B8.2 variable regions by using the Spot method of parallel peptide synthesis (13) . Whereas the Spot method has often been used to map interaction sites in epitopes (14) , study of the antibody paratope (15) by probing overlapping peptides covering the variable regions of an antibody with labelled antigen was contrary to accepted dogma, probably due to the widely held view that the three-dimensional structure of the antibody is absolutely required for antigen binding. Initial experiments on defining residues critical for lysozyme binding in the HyHEL-5 antibody paratope (16) by the Spot method indirectly suggested that Spot critical residues (SCR) are involved in the "true" antibody paratope since around 65% of identified SCR correlated with contributing residues previously defined by X-ray crystallography of the by guest on January 21, 2018 http://www.jbc.org/
Downloaded from
Analysis of contributing residues from the 13B8.2 paratope 5 lysozyme/HyHel-5 complex (17, 18) . Until now no direct demonstration, by simultaneous investigation using site-directed mutagenesis of the whole protein and Spot technology, has
shown that SCR from a given antibody actually belong to the paratope.
In this study on the mapping of key residues of the 13B8.2 Fab involved in CD4 recognition, we first identified residues important for binding by the Spot approach; then we used this information to design singly mutated recombinant 13B8.2 Fab. These mutated recombinant molecules showed far-UV circular dichroism spectra similar to that obtained for were performed before and after saturating plates in 1% nonfat powdered milk in PBS-T for 1 h at 37°C. Thereafter, 100 µl of two-fold serial dilutions of a 2.5 µg/ml antibody solution was added to each well. Following incubation for two hours and four washes in PBS-T, bound antibodies were detected by addition of 100 µl of a 1:1000 solution of peroxidase-conjugated anti-human kappa chain (Sigma), followed by subsequent addition of peroxidase substrate.
Absorbance was measured at 490 nm (A 490 Hepes pH 7.4, 3 mM EDTA, 150 mM NaCl, 0.005% P20) were then injected at concentrations between 5 and 20 µg/ml over the flow cell and the dissociation phase was followed by a regeneration step with a 5 mM HCl solution. The flow rate was 30 µl/min. All the sensorgrams were corrected by subtracting the low signal from the control reference surface.
The data were globally fitted to a 1:1 Langmuir binding isotherm using BIA evaluation 3. Analysis of contributing residues from the 13B8.2 paratope 10 absence of Fab for three days, harvested, and lysed. β-galactosidase activity was then determined as previously described by measuring the absorbance at 410 nm (27) . kDa (data not shown), corresponding to the expected size of a correctly-processed Fab under non-reducing conditions. The identity of the 50-kDa band was confirmed by Western blot using an anti-human κ chain (Fig. 2B) . As examplified for the alanine-mutated Fab H91-L and R53-H whose CD4-binding activities were the most drastically affected, and compared with wild-type Fab 13B8.2 ( Fig.2C) , a far-UV CD spectrum similar to that obtained for wild- (Fig. 7) . The structure of 1fdl and 1nld antibodies provided the template for the 13B8.2 light and heavy chain FW respectively. CDR conformations, except for CDR-H3, were predicted based on canonical classes. The most sequence-homologous known loops of the same canonical classes were used. CDR-L1, CDR-L2, and CDR-L3 were built using the 3D-antibody structure 1fdl, and CDR-H1 and CDR-H2 were built using the 1nld structure. The flexible CDR-H3 loop was not described as a canonical class and was built using a database search combined with a conformational search (CONGEN). The structure, as expected, presented two disulfide bridges, between Cys 22 and Cys 92 of the β-sheet of the heavy chain and Cys 23 and Cys 88 from the β-sheet of the light chain.
When positioned on the 13B8.2 model, the SCR were found to fall into four groups, depending on their location, solvent accessibility, and side-chain orientation in the model, together with their "true" involvement as defined by site-directed mutagenesis ( Fig. 7) : group 1 (red) for well-exposed SCR and group 2 (pink) for less accessible SCR, whose mutation affected CD4 reactivity; group 3 (blue) for well-exposed residues and group 4 (turquoise) for buried amino acids, whose mutant reactivity was not affected by site-directed mutagenesis. ) and/or were at a distance from the CD4-binding pocket like for Tyr 102 (Fig. 7) . More specifically, the two cysteines are not accessible to the solvent and are involved in disulfide bridges, which might decrease their probability to interact with CD4. Most In this paper, we used an approach based on the identification of residues critical for antigen binding by methods of parallel peptide synthesis combined with site-directed mutagenesis. Alanine scanning of previously-defined CD4-binding peptides (13) One major question is how can interactions between an antigen and its combining site on the antibody be predicted from studies based on antigen interaction with cellulosebound peptide fragments of the paratope? We can assume that probing such overall interaction can be assimilated to the mapping of discontinuous epitopes by the Spot method (33, 34) . In our case, the binding sites corresponding to the antigen-binding pocket were found to be distributed over most if not all the CDR, located far apart in the primary structure, Our results might be explained by gluthatione derivatization of the residual cysteine as described for yeast expression of the Cys-defective mutant lysozyme (44) or suggested for expression of Cys-defective whole antibodies (45) .
We cannot exclude that other residues, mainly located in the CDR-H3 and -L3 regions and not identified by the Spot method, contribute to CD4 binding. As suggested by computer- (less than 10% ELISA activity as compared with the wild-type Fab). Taken together, these observations outline the need to combine molecular modeling of the variable regions of a given antibody with 6-mer/12-mer Spot alascan analysis of the paratope to accurately define critical residues for antigen binding.
Although no structure of any CD4/antibody complex has yet been described, molecular modeling of the OKT4A antibody, which recognizes an epitope in the CDR2-like loop of domain 1 of CD4, has permitted the study of its antibody combining site (4). Analysis of contributing residues from the 13B8. The model is shown with side chains for each selected Spot critical residue from the 13B8.2 paratope, using different colors relative to the SCR groups (red for group 1, pink for group 2, blue for group 3, turquoise for group 4). SCR confirmed by site-directed mutagenesis experiments are identified in red or pink, whereas those not confirmed are in blue or turquoise.
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